Skip to content

Study of absorption and elimination rate of Sertraline 100-mg tablets in comparison with Sertraline brand tablets (Zoloft®).

Comparative bioequivalence study of the Sertraline 100-mg Tablets manufactured by Modava Company with Sertraline brand tablets (Zoloft®) produced by Pfizer company

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200407046981N46
Enrollment
24
Registered
2022-10-20
Start date
2022-12-22
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bioequivalence study.

Interventions

Intervention 1: Intervention group 1: In this group, volunteers are given a single oral dose of Sertraline 100-mg tablets produced by Modava Co. (Domestic). In each period, 12 of 24 subjects will be g

Sponsors

Modava Pharmaceutical Company
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Healthy male volunteers in the age range of 18-60 years old The weight limit of each volunteer should be between 60 and 100 kg. Body mass index should be between18-30 All volunteers must be non-smokers They must be healthy in terms of liver, kidney, respiratory system, mental and other general health characteristics that will be assessed Candidates who have consented to the consent form

Exclusion criteria

Exclusion criteria: Known hypersensitivity or idiosyncratic reaction to Sertralin or any ingredients. Subjects with BP = 90/60 mm/Hg or BP = 140/90 mm/Hg. Taking any medicine during two week before dosing. Any effects of renal, hepatic, cardiac, pulmonary or gastrointestinal dysfunction Any history of tuberculosis, seizures, asthma, diabetes, insanity or glaucoma

Design outcomes

Primary

MeasureTime frame
Peak Plasma Concentration (Cmax). Timepoint: 0 (before dosing), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48 and 72 hours after dosing. Method of measurement: High-performance liquid chromatography—mass spectrometry (HPLC-MS).

Secondary

MeasureTime frame
AUC (Area Under the Concentration-Time Curve). Timepoint: 0 (before dosing), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48 and 72 hours after dosing. Method of measurement: Using non-compartmental model of Win-Nonlin Professional software version 3.2.A (Pharsight Corporation, USA) or SPSS.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatima Molavi

Tabriz University of Medical Sciences

Molavif@tbzmed.ac.ir+98 41 3336 2700

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026